Stocks in Focus on June 3: Domestic shares spurted on Tuesday, June 2, 2020, extended its winning run to fifth straight session. Buying was broad-based with private banks in the lead. The barometer S&P BSE Sensex jumped 522.01 points or 1.57% at 33,825.53. The Nifty 50 index gained 152.95 points or 1.56% at 9,979.10. Both these indices have jumped 10.5% in five sessions. But certain stocks came in news after the market was closed. These stocks can impact the indices when it reopens on Wednesday, June 3, 2020. List of such five stocks:

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Britannia/ IndiGo/ Granule/ SPARC/ Dhampur/ Spandana Sphoorty: These are some companies that reported their financial results of March quarter FY20 after the market hours on Tuesday, June 2, 2020. Find details: 

Britannia Industries: The Biscuit maker on Tuesday reported a consolidated profit of Rs 374 crore for March quarter, registering a 26% year-on-year growth. The company had posted profit at Rs 297 crore in the corresponding period last fiscal. The profit was driven by cost efficiency programmes and moderate inflation in raw materials prices, even as revenue grew at a tepid pace. Revenue from operations for the quarter grew by 2.5% to Rs 2,867.7 crore against Rs 2,799 crore posted in the same period last year. EBITDA grew 4% to Rs 454 crore against Rs 436 crore. The margin was 15.8% against 15.6% of last year.

See Zee Business Live TV streaming below:

IndiGo: The airline on Tuesday posted the financial results of March quarter that ended on March 31, 2020, and reported a standalone loss of Rs 873 crore against a profit of Rs 590 crore in the corresponding quarter last year. Revenue from operation increased 5.3% at Rs 8,299 crore against Rs 7,883 crore. EBITDA stood at Rs 86.7 crore, down 96%, from Rs 2201.9 crore. Margin declined to 1% against 27.9% reported in the same period last year.
 
Granules India: The net profit of Granules India grew 13.9% in the March quarter that ended on March 31, 2020, at Rs 321 crore. The company posted a profit of Rs 282 crore in the same period a year ago. However, the revenue contracted by 2.2% to Rs 599 crore against Rs 613 crore of last year. Revenue de-grew due to restriction imposed on export of Paracetamol, API, PFI & FD's and disruption in logistics. EBITDA stood at Rs 99.9 crore, up 2.3%, against Rs 97.6 crore posted last year. Margins grew to 16.3% against 16.2%.

Sun Pharma Advanced Research Company Ltd (SPARC): The bio-pharmaceutical company posted the financial results of the March quarter on Tuesday and reported a loss of Rs 102.6 crore against a loss of Rs 7.4 crore posted a year ago in the corresponding quarter. Revenue fell 73% to Rs 22.7 crore against Rs 84.8 crore posted last year in the same period. 

Dhampur Sugar: The company on Tuesday posted the financial results for the year ended on March 31, 2020, and reported a 4% year-on-year decline in net profit at Rs 104 crore. The company posted a net profit of Rs 108.8 crore a year ago in the same quarter. Sales grew 25.4% to Rs 1,087.7 crore against Rs 867 crore. EBITDA fell 36% to Rs 117.7 crore from Rs 184.9 crore posted last year. Margins declined to 10.8% from 21.3%.
 
Spandana Sphoorty Financial Ltd: The company on Tuesday posted the financial results of March quarter FY20 and reported a 12.7% year-on-year increase in consolidated profit at Rs 83 crore. It posted a net profit of Rs 73.6 crore a year ago in the same quarter. Revenue from operations rose 61% to Rs 428.6 crore against Rs 265.2 crore. EBITDA stood at Rs 182.2 crore, down 7%, from Rs 196.4 crore. 

Adani Power + Reliance Industries: The Board of Adani Power will meet today, on June 3, 2020, to discuss on the delisting of the company's shares from the stock exchanges. Besides, today is the last day for the subscription of the Reliance Industries mega Rs 53,124 crore rights issue. The issue is the largest in the world by a non-financial issuer in the last 10 years. 

Lupin + Syngene: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the US FDA, to market a generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly. Meloxicam Capsules, 5 mg and 10 mg, are indicated for the management of osteoarthritis (OA) pain. The annual sales of the drug in the US stand around $ 14 million. Besides, Syngene International, an integrated research and development services company, has entered into a collaboration with HiMedia Laboratories to manufacture and distribute its ELISA kits. This advanced highly reliable test identifies the presence of SARS-COV-2 antibodies in blood samples and confirms if a patient has been exposed to the coronavirus. HiMedia will manufacture the kits at its facility in Mumbai and distribute it across India. HiMedia Laboratories is a bioscience company with expertise in media manufacturing and diagnostics for over 45 years.

ICICI Bank: ICICI Bank on Tuesday said it has cut the interest rate on saving deposits by 25 basis points (bps). The new rates will come into effect from Thursday, June 4, 2020. ICICI Bank has cut the interest rate on all deposits of less than Rs 50 lakh to 3 per cent, a reduction of by 25 bps as against the existing 3.25 per cent. The interest rate on savings bank balance of Rs 50 lakhs and above has been revised from 3.75% per annum to 3.50% per annum.

Vedanta: UK’s Vedanta Resources (VRL) has appointed US-based shareholder engagement firm Georgeson to convince shareholders to accept its delisting process for India’s Vedanta Ltd (VDL). VRL holds 50 per cent stake in VDL and it requires 40 per cent more to delist the company from Indian stock exchanges.